rethinkTHC Search
Menu
Study breakdown

The body breaks down the endocannabinoid anandamide through multiple enzyme pathways with distinct products

ReviewModerate evidence
The takeaway

A review detailed how cytochrome P450 enzymes metabolize anandamide into structurally diverse lipids, some of which activate cannabinoid receptors, complicating the development of FAAH inhibitor drugs.

Read this if you are interested in the biochemistry of how the body processes endocannabinoids and implications for drug development.

A P450-derived anandamide metabolite is a potent CB2 receptor agonist

What the researchers found

The review focused on an underappreciated aspect of endocannabinoid biology: the oxidation of anandamide by cytochrome P450 enzymes.

While FAAH is the primary enzyme that breaks down anandamide, several P450 enzymes (CYP3A4, CYP4F2, CYP4X1, and the highly variable CYP2D6) also metabolize anandamide into structurally diverse lipid products.

Critically, one P450-derived epoxide of anandamide was found to be a potent agonist at CB2 receptors. This meant that blocking FAAH alone (the approach being developed for pain treatment) might not fully control endocannabinoid signaling because alternative metabolic pathways would still produce active compounds.

The genetic variability in CYP2D6 across individuals could lead to different responses to endocannabinoid-targeting drugs.

Why it matters

Understanding that multiple enzyme systems process anandamide into bioactive products was essential for developing effective endocannabinoid-targeting drugs, particularly FAAH inhibitors being developed for pain and inflammation.

The numbers in context

Four P450 enzymes identified: CYP3A4, CYP4F2, CYP4X1, CYP2D6. One P450-derived epoxide was a potent CB2 agonist. CYP2D6 is highly polymorphic across populations.

How the study worked

Comprehensive review published in Pharmacological Reviews examining the cytochrome P450-mediated oxidation pathways of anandamide, their physiological significance, and implications for drug development.

What this study cannot tell us

Much of the evidence came from in vitro enzyme studies. The physiological relevance of P450-mediated anandamide metabolism in vivo required further investigation. The clinical implications were still theoretical.

How to read the evidence

Comprehensive review in a leading pharmacology journal synthesizing biochemical evidence across multiple enzyme pathways.

When this study was published

Published in 2010. FAAH inhibitor development has continued with these complexities in mind.

The bigger picture

This research highlighted the complexity of the endocannabinoid system beyond simple production and degradation, with multiple metabolic pathways generating diverse bioactive lipids that could influence therapeutic outcomes.

Questions still open

  • How do P450-mediated anandamide metabolites contribute to endocannabinoid signaling in vivo? Should FAAH inhibitor drug development account for these alternative metabolic pathways?

Common questions

What does this have to do with cannabis?
Anandamide is the body's own cannabinoid. Understanding how it is processed and broken down is essential for developing drugs that target the same system as cannabis, such as pain medications that boost endocannabinoid levels.
Why does genetic variation in CYP2D6 matter?
CYP2D6 varies widely between individuals and populations. Since this enzyme processes anandamide into bioactive products, people with different CYP2D6 variants may have different endocannabinoid signaling and different responses to cannabis or endocannabinoid-targeting drugs.

Read the original research

Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.

Pharmacological reviews, 62(1), 136-54

Citation

Snider, Natasha T; Walker, Vyvyca J; Hollenberg, Paul F. (2010). Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.. Pharmacological reviews, 62(1), 136-54. https://doi.org/10.1124/pr.109.001081

Explore the wider topic